Trial reportWorld journal of gastroenterology2008
Role of 18F-fluorodeoxyglucose positron emission tomography imaging in surgery for pancreatic cancer.
Trial report in World journal of gastroenterology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Imaging modalities for characterising focal pancreatic lesions.The Cochrane database of systematic reviews · 2017Pooled it
- The Role of Endoscopic Ultrasonography in the Diagnosis and Staging of Pancreatic Cancer.Cancers · 2022Review
- Positron emission tomography and computed tomography with [European journal of nuclear medicine and molecular imaging · 2022Article
- Pancreatic adenocarcinoma: A review of recent paradigms and advances in epidemiology, clinical diagnosis and management.World journal of gastroenterology · 2021Review
- Conversion Therapy for Advanced Pancreatic Cancer: The Case Series and Literature Review.Frontiers in pharmacology · 2020Article
- Diagnostic accuracy of different imaging modalities following computed tomography (CT) scanning for assessing the resectability with curative intent in pancreatic and periampullary cancer.The Cochrane database of systematic reviews · 2016Review
- The clinical usefulness of 18F-fluorodeoxyglucose positron emission tomography-computed tomography (PET-CT) in follow-up of curatively resected pancreatic cancer patients.HPB : the official journal of the International Hepato Pancreato Biliary Association · 2016Article
- Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions.Radiology · 2015Article
- Cross-modality PET/CT and contrast-enhanced CT imaging for pancreatic cancer.World journal of gastroenterology · 2015Article
- Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer.World journal of gastroenterology · 2014Review
- Positron emission tomography (PET) has limited utility in the staging of pancreatic adenocarcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2014Article
- The role ofJournal of radiation oncology · 2013Article
- Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer.Yonsei medical journal · 2013Article
- FDG-PET/CT-based restaging may alter initial management decisions and clinical outcomes in patients with locally advanced pancreatic carcinoma planned to undergo chemoradiotherapy.Cancer imaging : the official publication of the International Cancer Imaging Society · 2013Article
- Ductal adenocarcinoma of the pancreatic head: a focus on current diagnostic and surgical concepts.World journal of gastroenterology · 2012Review
- Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.World journal of gastroenterology · 2011Review
- Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection.International journal of clinical oncology · 2011Article
- 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer.World journal of gastroenterology · 2011Article
- Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.Molecular imaging and biology · 2010Article
- Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the role of positron emission tomography using 18F-fluorodeoxyglucose (FDG-PET) in the surgical management of patients with pancreatic cancer, including the diagnosis, staging, and selection of patients for the subsequent surgical treatment.
methodsThis study involved 53 patients with proven primary pancreatic cancer. The sensitivity of diagnosing the primary cancer was examined for FDG-PET, CT, cytological examination of the bile or pancreatic juice, and the serum levels of carcinoembrionic antigens (CEA) and carbohydrate antigen 19-9 (CA19-9). Next, the accuracy of staging was compared between FDG-PET and CT. Finally, FDG-PET was analyzed semiquantitatively using the standard uptake value (SUV). The impact of the SUV on patient management was evaluated by examining the correlations between the SUV and the histological findings of cancer.
resultsThe sensitivity of FDG-PET, CT, cytological examination of the bile or pancreatic juice, and the serum levels of CEA and CA19-9 were 92.5%, 88.7%, 46.4%, 37.7% and 69.8%, respectively. In staging, FDG-PET was superior to CT only in diagnosing distant disease (bone metastasis). For local staging, the sensitivity of CT was better than that of FDG-PET. The SUV did not correlate with the pTNM stage, grades, invasions to the vessels and nerve, or with the size of the tumor. However, there was a statistically significant difference (4.6 +/- 2.9 vs 7.8 +/- 4.5, P = 0.024) in the SUV between patients with respectable and unresectable disease.
conclusionFDG-PET is thus considered to be useful in the diagnosis of pancreatic cancer. However, regarding the staging of the disease, FDG-PET is not considered to be a sufficiently accurate diagnostic modality. Although the SUV does not correlate with the patho-histological prognostic factors, it may be useful in selecting patients who should undergo subsequent surgical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.